BioIVT Joins Platform to Help Improve Drug Discovery Success Rates

September 27, 2019

Pharmaceutical Technology's In the Lab eNewsletter

In the Lab eNewsletter, Pharmaceutical Technology\'s In the Lab eNewsletter-10-02-2019, Volume 14, Issue 10

BioIVT has announced that it has joined the Medicines Discovery Catapult’s Discovery Services Platform, which is aimed at supporting drug discovery within the United Kingdom.

BioIVT has announced in a Sep. 24, 2019 press release that it has joined the Medicines Discovery Catapult’s Discovery Services Platform, which is aimed at supporting drug discovery within the United Kingdom.

As part of the platform, BioIVT will partner up with other service providers in the goal of progressing preclinical drug discovery and increase success rates. BioIVT’s PHASEZERO research services team will be used to provide support in the generation of human tissue-based target validation data as well as the characterization of novel therapeutics.

“BioIVT is dedicated to supporting the research community by providing expertise in human tissue-based approaches that deliver target and biomarker validation data and by developing fit-for-purpose assays that enable characterization of novel therapeutics to accelerate drug discovery and development,” said Amanda Woodrooffe, vice-president and general manager at BioIVT UK, in the press release. “We are delighted to join Medicines Discovery Catapult’s Discovery Services Platform and be able to provide our expertise, access to ethically-sourced human biospecimens, and innovative approaches to support UK enterprises.”

Source: BioIVT